REFERENCES
- Miura H., Onishi H., Sasatsu M., Machida Y. Antitumor characteristics of methoxypolyethylene glycol-poly(DL-lactic acid) nanoparticles containing camptothecin. J. Control. Rel. 2004; 97: 101–113
- Mehnert W., Mader K. Solid lipid nanoparticles. Production, characterization and applications. Adv. Drug Del. Rev. 2001; 47: 165–196
- Muller R. H., Mader K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur. J. Pharm. Biopharm. 2000; 50: 161–177
- Lasic D. D. Novel applications of liposomes. Tibtech 1998; 16: 307–321
- Heath T. H. Liposomes dependent drugs. Liposomes as Drug Carriers: Trends and Progress, G. Gregoriadis. Wiley, San Francisco 1988; 709–718
- Smith A., Hunneyball I. M. Evaluation of polylactid as a biodegradabledrug delivery system for parenteral administration. Int. J. Pharm. 1986; 30: 215–230
- Wissing S. A., Kayser O., Muller R. H. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Del. Rev. 2004; 56: 1257–1272
- Muller R. H., Radtke M., Wissing S. A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Del. Rev. 2002; 54(1)S131–S155
- Muller R. H., Radtke M., Wissing S. A. Nanostructured lipid matrices for improver microencapsulation of drugs. Int. J. Pharm. 2002; 242: 121–128
- Radtke M., Muller R. H. NLC-nanostructured lipid carriers: the new generation of lipid drug carriers. New Drugs 2001; 2: 97–138
- Jenning V., Thunemann A. F., Gohla S. H. Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int. J. Pharm. 2000; 199: 167–177
- Jenning V., Gohla S. Encapsulation of retinoids in solid lipid nanoparticles (SLN). J. Microencaps. 2001; 18: 149–158
- Jores K., Mehnert W., Drechsler M., et al. Investigation on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J. Control. Rel. 2004; 95: 217–227
- Diana P., Barraja P., Lauria A., et al. Pyrrolo[2,1-d][1,2,3,5]tetrazines, a new class of azolotetrazines related to the antitumor drug temozolomide. Synthesis 1999; 2082
- Grever M. R., Sherpartz S. A., Chabner B. A. The National Cancer Institute: cancer drug discovery and development program. Semin. Oncol. 1992; 19: 622–638
- Monks A. P., Scudiero D. A., Skehan P., et al. Feasibility of a high-flux anticancer drug screen utilizing a derived panel of human tumor cell lines in culture. J. Natl. Cancer Inst. 1991; 83: 757–766
- Weinstein J. N., Meyers T. G., O'Connor P. M., et al. An information–intensive approach to the molecular pharmacology of cancer. Science 1997; 275: 343–349
- Diana P., Barraja P., Lauria A., et al. Pyrrolo[2,1-d][1,2,3,5]tetrazine-4(3H)-ones, a new class of azolotetrazines with potent antitumor activity. Bioorg. Med. Chem. 2003; 11: 2371–2380
- Plowman J., Dykes D. J., Hollingshead M., et al. Anticancer Drug Development Guide. Preclinical Screening, Clinical Trials, and Approval, B. Teicher. Humana Press, Totowa, NJ 1997; 101–125
- Hollingshead M., Plowman J., Alley M. C., et al. The hollow fiber assay. Contrib. Oncol. 1999; 54: 109–120
- Brigger I., Dubernet C., Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Del. Rev. 2002; 54: 631–651
- Maeda H., Wu J., Sawa T., et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Rel. 2000; 65: 271–284
- Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001; 41: 189–207
- Noguchi Y., Wu J., Duncan R., et al. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 1998; 89: 307–314
- Scholer N., Hahn H., Muller R. H., Liesenfeld O. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int. J. Pharm. 2002; 231: 167–176